Literature DB >> 16928886

Recombinant bovine herpesvirus 4 (BoHV-4) expressing glycoprotein D of BoHV-1 is immunogenic and elicits serum-neutralizing antibodies against BoHV-1 in a rabbit model.

Gaetano Donofrio1, Sandro Cavirani, Alain Vanderplasschen, Laurent Gillet, Cesidio Filippo Flammini.   

Abstract

Several biological characteristics of bovine herpesvirus 4 (BoHV-4) make it a good candidate as a gene delivery vector for vaccination purposes. These characteristics include little or no pathogenicity, unlikely oncogenicity, the capability to accommodate large amounts of foreign genetic material, the ability to infect several cell types coming from different animal species, and the ability to maintain transgene expression in both undifferentiated and differentiated cells. Starting from BoHV-4 cloned as a bacterial artificial chromosome (BAC), we used MuA transposase-mediated in vitro transposition to generate recombinant BoHV-4 expressing the immunodominant glycoprotein D (gD) of BoHV-1, one of the most important pathogens of cattle. Although a cis-acting element from woodchuck hepatitis virus (the woodchuck hepatitis virus posttranscriptional regulatory element [WPRE]) in the 3' end of the gD expression cassette was required for maximal gD expression from plasmids in transient transfection assays, this element was not necessary for efficient expression of gD from recombinant BoHV-4 genomes. BoHV-4 recombinants containing gD expression cassettes with or without the WPRE expressed gD at similarly high levels. Several cell lines originating from different animal species expressed gD when infected with BoHV-4 recombinants. When rabbits were immunized with one of the recombinants, high levels of serum neutralizing antibodies against BoHV-1 were generated. This work is one of the first demonstrations of the use BoHV-4 as a vector for vaccine purposes and may provide the basis for BoHV-1 vaccination of cattle with recombinant BoHV-4.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928886      PMCID: PMC1656551          DOI: 10.1128/CVI.00200-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Propagation and quantitation of animal herpesviruses in eight cell culture systems.

Authors:  R B Peterson; S M Goyal
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1988       Impact factor: 2.268

2.  Experimental infection of bulls with a genital isolate of bovine herpesvirus-4 and reactivation of latent virus with dexamethasone.

Authors:  J Dubuisson; E Thiry; M Bublot; I Thomas; M F van Bressem; F Coignoul; P P Pastoret
Journal:  Vet Microbiol       Date:  1989-12       Impact factor: 3.293

3.  Biological and biochemical comparison of bovid herpesvirus-4 strains.

Authors:  J Dubuisson; E Thiry; F Thalasso; M Bublot; P P Pastoret
Journal:  Vet Microbiol       Date:  1988-04       Impact factor: 3.293

4.  Outcome of bovine herpesvirus 4 infection following direct viral injection in the lateral ventricle of the mouse brain.

Authors:  Gaetano Donofrio; Andrea Cavaggioni; Michela Bondi; Sandro Cavirani; Cesidio Filippo Flammini; Carla Mucignat-Caretta
Journal:  Microbes Infect       Date:  2006-02-03       Impact factor: 2.700

5.  A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells.

Authors:  J Yates; N Warren; D Reisman; B Sugden
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

6.  Analysis of bovine cytomegalovirus genome structure: cloning and mapping of the monomeric polyrepetitive DNA unit, and comparison of European and American strains.

Authors:  B Ehlers; H J Buhk; H Ludwig
Journal:  J Gen Virol       Date:  1985-01       Impact factor: 3.891

7.  Genetic relationships between bovine herpesvirus 4 and the gammaherpesviruses Epstein-Barr virus and herpesvirus saimiri.

Authors:  M Bublot; P Lomonte; A S Lequarre; J C Albrecht; J Nicholas; B Fleckenstein; P P Pastoret; E Thiry
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

8.  Persistence of bovid herpesvirus-4 in experimentally inoculated pregnant rabbits.

Authors:  K Naeem; D D Caywood; S M Goyal; R E Werdin; M P Murtaugh
Journal:  New Microbiol       Date:  1993-01       Impact factor: 2.479

9.  Studies on the pathogenesis of a bovine cytomegalo-like virus in an experimental host.

Authors:  F A Osorio; D L Rock; D E Reed
Journal:  J Gen Virol       Date:  1985-09       Impact factor: 3.891

10.  Experimental inoculation of cattle with bovine herpesvirus-4: evidence for a lymphoid-associated persistent infection.

Authors:  F A Osorio; D E Reed
Journal:  Am J Vet Res       Date:  1983-06       Impact factor: 1.156

View more
  9 in total

1.  Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development.

Authors:  Gaetano Donofrio; Valentina Franceschi; Antonio Capocefalo; Simone Taddei; Chiara Sartori; Sabrina Bonomini; Sandro Cavirani; Clotilde S Cabassi; Cesidio F Flammini
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

2.  In vivo image analysis of BoHV-4-based vector in mice.

Authors:  Valentina Franceschi; Fabio Franco Stellari; Carlo Mangia; Sarah Jacca; Sophia Lavrentiadou; Sandro Cavirani; Mathias Heikenwalder; Gaetano Donofrio
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

3.  A recombinant bovine herpesvirus-4 vectored vaccine delivered via intranasal nebulization elicits viral neutralizing antibody titers in cattle.

Authors:  Laura B A Williams; Lindsay M Fry; David R Herndon; Valentina Franceschi; David A Schneider; Gaetano Donofrio; Donald P Knowles
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

4.  Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR-/- Mice Models.

Authors:  Touraj Aligholipour Farzani; Katalin Földes; Alireza Hanifehnezhad; Burcu Yener Ilce; Seval Bilge Dagalp; Neda Amirzadeh Khiabani; Koray Ergünay; Feray Alkan; Taner Karaoglu; Hurrem Bodur; Aykut Ozkul
Journal:  Viruses       Date:  2019-03-09       Impact factor: 5.048

5.  Clinical protection of goats against CpHV-1 induced genital disease with a BoHV-4-based vector expressing CpHV-1 gD.

Authors:  Gaetano Donofrio; Valentina Franceschi; Angela Lovero; Antonio Capocefalo; Michele Camero; Michele Losurdo; Sandro Cavirani; Mariarosaria Marinaro; Erika Grandolfo; Canio Buonavoglia; Maria Tempesta
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

6.  Establishment of a bovine herpesvirus 4 based vector expressing a secreted form of the bovine viral diarrhoea virus structural glycoprotein E2 for immunization purposes.

Authors:  Gaetano Donofrio; Chiara Sartori; Lara Ravanetti; Sandro Cavirani; Laurent Gillet; Alain Vanderplasschen; Simone Taddei; Cesidio Filippo Flammini
Journal:  BMC Biotechnol       Date:  2007-10-18       Impact factor: 2.563

7.  BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge.

Authors:  Valentina Franceschi; Scott Parker; Sarah Jacca; Ryan W Crump; Konstantin Doronin; Edguardo Hembrador; Daniela Pompilio; Giulia Tebaldi; Ryan D Estep; Scott W Wong; Mark R Buller; Gaetano Donofrio
Journal:  PLoS Negl Trop Dis       Date:  2015-06-18

Review 8.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

9.  Development of a BoHV-4 viral vector expressing tgD of BoHV-1 and evaluation of its immunogenicity in mouse model.

Authors:  Seval Bilge-Dagalp; Touraj Aligholipour Farzani; Firat Dogan; Zeynep Akkutay Yoldar; Aykut Ozkul; Feray Alkan; Gaetano Donofrio
Journal:  Braz J Microbiol       Date:  2021-07-13       Impact factor: 2.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.